News
Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will provide a corporate presentation at the H.C. Wainwright BIOCONNECT Virtual Conference on
Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the management team will participate in two upcoming virtual investor conferences.
-
H.C. Wainwright
Puma Biotechnology to Present at the H.C. Wainwright BioConnect Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of
Poxel Announces Financial Calendar for 2022
POXEL SA (Euronext – POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic
Savara to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright BIOCONNECT
Deciphera Pharmaceuticals, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference
NanoString to Webcast Presentation from the 40th Annual JP Morgan Healthcare Conference
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a
Simulations Plus Sets Date for First Quarter Fiscal Year 2022 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the first quarter of fiscal year 2022, the period ended November 30, 2021, after the close of the
Ipsen und GENFIT schließen im Rahmen einer langfristigen globalen Partnerschaft eine exklusive Lizenzvereinbarung für Elafibranor ab, ein Phase-III-Asset, das für die Behandlung von primärer biliärer Cholangitis geprüft wird
Disclaimer: Nur für internationale Medien und Investoren bestimmt
Diese Pressemitteilung enthält multimediale Inhalte. Die vollständige Mitteilung hier ansehen: https://www.businesswire.com/news/h
Transgene Announces Investor Meetings for January 2022
Regulatory News:
TRANSGENE (Paris:TNG) today announces that Management will participate in the upcoming investor events set out below.
Transgene will meet institutional investors at the 11th
Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216006159/en/
Disclaimer: Intended for international media and
Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces that AstraZeneca
Poxel Announces its Participation at Upcoming Investor and Scientific Conferences in January 2022
POXEL SA (Euronext – POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
GeNeuro erhält von der Schweizer Regierung Finanzmittel in Höhe von 6,7 Millionen Schweizer Franken (6,4 Millionen Euro) für die Entwicklung von Temelimab gegen Long COVID
GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO), ein biopharmazeutisches Unternehmen, das neue Therapien für neurodegenerative und Autoimmunerkrankungen entwickelt, meldete heute, dass
Geneuro Receives CHF 6.7 Million (EUR 6.4 Million) in Funding From the Swiss Government for the Development of Temelimab Against Long-COVID
Regulatory News:
GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, with final
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene
Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary proof-of-concept clinical data from the Phase 1/2 PRECIZN-1 study of SAR445136, a zinc
Puma Biotechnology Presents Updates from the SUMMIT Trial at the 2021 SABCS Annual Meeting
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented an update from its Phase II SUMMIT trial at the ongoing 2021 San Antonio Breast Cancer Symposium (SABCS) Annual
Clovis Oncology Highlights FAP-2286 Preclinical Data Presented at the Targeted Radiopharmaceuticals Summit
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today’s presentation by Andrew D. Simmons, Ph.D., Clovis’ Senior Vice President, Translational Medicine, at the 3rd Targeted Radiopharmaceuticals
Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN)
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
Regulatory News:
Nanobiotix (Paris:NANO) (NASDAQ:NBTX):
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website
Poxel Announces the Formation of its Scientific Advisory Board for Rare Metabolic Diseases
POXEL SA (Euronext – POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic diseases with metabolic pathophysiology, including non-alcoholic
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that on December 1, 2021, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees.
On December 1